Atherosclerosis - A matter of unresolved inflammation

Seminars in Immunology

Volumn 27, Issue 3, 2015, Pages 184-193

  Viola, Joana ^a   Soehnlein, Oliver ^a,b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Atherosclerosis; Efferocytosis; Inflammation resolution; Macrophage polarization

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CD36 ANTIGEN; CD59 ANTIGEN; COLONY STIMULATING FACTOR 1; GALECTIN 1; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LIPOCORTIN 1; LIPOXIN A; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 7; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PENTRAXIN 3; ANTIINFLAMMATORY AGENT;

ATHEROSCLEROSIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; EFFECTOR CELL; HUMAN; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MONOCYTE; NONHUMAN; PHAGOCYTE; REVIEW; APOPTOSIS; IMMUNOLOGY; LIPID METABOLISM; PATHOLOGY; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LEUKOCYTES; LIPID METABOLISM; MACROPHAGES; WOUND HEALING;

EID: 84937526685     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.03.013     Document Type: Review

References (155)

1. Boren J., Olin K., Lee I., Chait A., Wight T.N., Innerarity T.L. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Investig. 1998, 101:2658-2664.
2. Kwon G.P., Schroeder J.L., Amar M.J., Remaley A.T., Balaban R.S. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation 2008, 117:2919-2927.
3. Salvayre R., Auge N., Benoist H., Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. Biochim. Biophys. Acta 2002, 1585:213-221.
4. Liu J., Thewke D.P., Su Y.R., Linton M.F., Fazio S., Sinensky M.S. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:174-179.
5. van Vlijmen B.J., Gerritsen G., Franken A.L., Boesten L.S., Kockx M.M., Gijbels M.J., et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. 2001, 88:780-786.
6. Ortega-Gomez A., Perretti M., Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol. Med. 2013, 5:661-674.
7. Soehnlein O., Drechsler M., Doring Y., Lievens D., Hartwig H., Kemmerich K., et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol. Med. 2013, 5:471-481.
8. Ylitalo R., Oksala O., Yla-Herttuala S., Ylitalo P. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J. Lab. Clin. Med. 1994, 123:769-776.
9. Stoneman V., Braganza D., Figg N., Mercer J., Lang R., Goddard M., et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ. Res. 2007, 100:884-893.
10. -/- mice during disease regression. J. Clin. Investig. 2011, 121:2025-2036.
11. Drechsler M., Megens R.T., van Zandvoort M., Weber C., Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010, 122:1837-1845.
12. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ. Res. 2012, 110:875-888.
13. Swirski F.K., Pittet M.J., Kircher M.F., Aikawa E., Jaffer F.A., Libby P., et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10340-10345.
14. Tacke F., Alvarez D., Kaplan T.J., Jakubzick C., Spanbroek R., Llodra J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Investig. 2007, 117:185-194.
15. Landsman L., Bar-On L., Zernecke A., Kim K.W., Krauthgamer R., Shagdarsuren E., et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009, 113:963-972.
16. Robbins C.S., Hilgendorf I., Weber G.F., Theurl I., Iwamoto Y., Figueiredo J.L., et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 2013, 19:1166-1172.
17. Zhu S.N., Chen M., Jongstra-Bilen J., Cybulsky M.I. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J. Exp. Med. 2009, 206:2141-2149.
18. Randolph G.J. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr. Opin. Lipidol. 2008, 19:462-468.
19. Assinger A., Wang Y., Butler L.M., Hansson G.K., Yan Z.Q., Soderberg-Naucler C., et al. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses. Thromb. Haemost. 2014, 112:332-341.
20. von Hundelshausen P., Weber K.S., Huo Y., Proudfoot A.E., Nelson P.J., Ley K., et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001, 103:1772-1777.
21. Badrnya S., Schrottmaier W.C., Kral J.B., Yaiw K.C., Volf I., Schabbauer G., et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler. Thromb. Vasc. Biol. 2014, 34:571-580.
22. Siegel-Axel D., Daub K., Seizer P., Lindemann S., Gawaz M. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc. Res. 2008, 78:8-17.
23. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 2003, 9:61-67.
24. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 2002, 196:887-896.
25. Burger P.C., Wagner D.D. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003, 101:2661-2666.
26. Postea O., Vasina E.M., Cauwenberghs S., Projahn D., Liehn E.A., Lievens D., et al. Contribution of platelet CX(3)CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1186-1193.
27. Badrnya S., Butler L.M., Soderberg-Naucler C., Volf I., Assinger A. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb. Haemost. 2012, 108:719-729.
28. Lam F.W., Burns A.R., Smith C.W., Rumbaut R.E. Platelets enhance neutrophil transendothelial migration via P-selectin glycoprotein ligand-1. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H468-H475.
29. Tsimikas S., Brilakis E.S., Miller E.R., McConnell J.P., Lennon R.J., Kornman K.S., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 2005, 353:46-57.
30. Ravandi A., Leibundgut G., Hung M.Y., Patel M., Hutchins P.M., Murphy R.C., et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J. Am. Coll. Cardiol. 2014, 63:1961-1971.
31. Jeney V., Balla G., Balla J. Red blood cell, hemoglobin and heme in the progression of atherosclerosis. Front. Physiol. 2014, 5:379.
32. Kockx M.M., Cromheeke K.M., Knaapen M.W., Bosmans J.M., De Meyer G.R., Herman A.G., et al. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:440-446.
33. Kolodgie F.D., Gold H.K., Burke A.P., Fowler D.R., Kruth H.S., Weber D.K., et al. Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 2003, 349:2316-2325.
34. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
35. Hagberg I.A., Roald H.E., Lyberg T. Adhesion of leukocytes to growing arterial thrombi. Thromb. Haemost. 1998, 80:852-858.
36. Kirchhofer D., Riederer M.A., Baumgartner H.R. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997, 89:1270-1278.
37. Ghasemzadeh M., Kaplan Z.S., Alwis I., Schoenwaelder S.M., Ashworth K.J., Westein E., et al. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood 2013, 121:4555-4566.
38. Coffey M.J., Phare S.M., Peters-Golden M. Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J. Immunol. 2000, 165:3592-3598.
39. Lee E., Lindo T., Jackson N., Meng-Choong L., Reynolds P., Hill A., et al. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am. J. Respir. Crit. Care Med. 1999, 160:2079-2085.
40. Ott V.L., Cambier J.C., Kappler J., Marrack P., Swanson B.J. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol. 2003, 4:974-981.
41. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220:568-575.
42. Yokomizo T., Izumi T., Chang K., Takuwa Y., Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
43. Matsukawa A., Hogaboam C.M., Lukacs N.W., Lincoln P.M., Strieter R.M., Kunkel S.L. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J. Immunol. 1999, 163:6148-6154.
44. Subbarao K., Jala V.R., Mathis S., Suttles J., Zacharias W., Ahamed J., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. 2004, 24:369-375.
45. Huang L., Zhao A., Wong F., Ayala J.M., Struthers M., Ujjainwalla F., et al. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1783-1788.
46. Mehrabian M., Allayee H., Wong J., Shi W., Wang X.P., Shaposhnik Z., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 2002, 91:120-126.
47. Qiu H., Gabrielsen A., Agardh H.E., Wan M., Wetterholm A., Wong C.H., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8161-8166.
48. Spanbroek R., Grabner R., Lotzer K., Hildner M., Urbach A., Ruhling K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1238-1243.
49. Toda A., Yokomizo T., Masuda K., Nakao A., Izumi T., Shimizu T. Cloning and characterization of rat leukotriene B(4) receptor. Biochem. Biophys. Res. Commun. 1999, 262:806-812.
50. Assimes T.L., Knowles J.W., Priest J.R., Basu A., Borchert A., Volcik K.A., et al. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis 2008, 198:136-144.
51. Wittwer J., Bayer M., Mosandl A., Muntwyler J., Hersberger M. The c.-292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective. Clin. Chem. Lab. Med.: CCLM/FESCC 2007, 45:487-492.
52. Merched A.J., Ko K., Gotlinger K.H., Serhan C.N., Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J.: Off. Publ. Feder. Am. Soc. Exp. Biol. 2008, 22:3595-3606.
53. Hajishengallis G., Chavakis T. Endogenous modulators of inflammatory cell recruitment. Trends Immunol. 2013, 34:1-6.
54. Deban L., Russo R.C., Sironi M., Moalli F., Scanziani M., Zambelli V., et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat. Immunol. 2010, 11:328-334.
55. Choi E.Y., Chavakis E., Czabanka M.A., Langer H.F., Fraemohs L., Economopoulou M., et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 2008, 322:1101-1104.
56. Cooper D., Norling L.V., Perretti M. Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 2008, 83:1459-1466.
57. La M., Cao T.V., Cerchiaro G., Chilton K., Hirabayashi J., Kasai K., et al. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am. J. Pathol. 2003, 163:1505-1515.
58. Kempf T., Zarbock A., Widera C., Butz S., Stadtmann A., Rossaint J., et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med. 2011, 17:581-588.
59. Norata G.D., Marchesi P., Pulakazhi Venu V.K., Pasqualini F., Anselmo A., Moalli F., et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
60. Savchenko A., Imamura M., Ohashi R., Jiang S., Kawasaki T., Hasegawa G., et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J. Pathol. 2008, 215:48-55.
61. Preusch M.R., Baeuerle M., Albrecht C., Blessing E., Bischof M., Katus H.A., et al. GDF-15 protects from macrophage accumulation in a mousemodel of advanced atherosclerosis. Eur. J. Med. Res. 2013, 18:19.
62. Bonaterra G.A., Zugel S., Thogersen J., Walter S.A., Haberkorn U., Strelau J., et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J. Am. Heart Assoc. 2012, 1:e002550.
63. de Jager S.C., Bermudez B., Bot I., Koenen R.R., Bot M., Kavelaars A., et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J. Exp. Med. 2011, 208:217-225.
64. Johnen H., Kuffner T., Brown D.A., Wu B.J., Stocker R., Breit S.N. Increased expression of the TGF-b superfamily cytokine MIC-1/GDF15 protects ApoE(-/-) mice from the development of atherosclerosis. Cardiovasc. Pathol.: Off. J. Soc. Cardiovasc. Pathol. 2012, 21:499-505.
65. Drechsler M., de Jong R.J., Rossaint J., Viola J., Leoni G., Wang J.M., et al. Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ. Res. 2015, 116:827-835.
66. Rosenfeld M.E. Macrophage proliferation in atherosclerosis: an historical perspective. Arterioscler. Thromb. Vasc. Biol. 2014, 34:e21-e22.
67. Fuster J.J., Fernandez P., Gonzalez-Navarro H., Silvestre C., Nabah Y.N., Andres V. Control of cell proliferation in atherosclerosis: insights from animal models and human studies. Cardiovasc. Res. 2010, 86:254-264.
68. Sayin V.I., Khan O.M., Pehlivanoglu L.E., Staffas A., Ibrahim M.X., Asplund A., et al. Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53. Circ. Res. 2014, 115:781-789.
69. Wu G., Cai J., Han Y., Chen J., Huang Z.P., Chen C., et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation 2014, 130:1452-1465.
70. Hashimoto D., Chow A., Noizat C., Teo P., Beasley M.B., Leboeuf M., et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013, 38:792-804.
71. Jenkins S.J., Ruckerl D., Cook P.C., Jones L.H., Finkelman F.D., van Rooijen N., et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011, 332:1284-1288.
72. Gautier E.L., Huby T., Witztum J.L., Ouzilleau B., Miller E.R., Saint-Charles F., et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009, 119:1795-1804.
73. Sleiman L., Beanlands R., Hasu M., Thabet M., Norgaard A., Chen Y.X., et al. Loss of cellular inhibitor of apoptosis protein 2 reduces atherosclerosis in atherogenic apoE-/- C57BL/6 mice on high-fat diet. J. Am. Heart Assoc. 2013, 2:e000259.
74. Hamada M., Nakamura M., Tran M.T., Moriguchi T., Hong C., Ohsumi T., et al. MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. Nat. Commun. 2014, 5:3147.
75. Sallam T., Ito A., Rong X., Kim J., van Stijn C., Chamberlain B.T., et al. The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis. J. Lipid Res. 2014, 55:1120-1130.
76. Bellingan G.J., Caldwell H., Howie S.E., Dransfield I., Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J. Immunol. 1996, 157:2577-2585.
77. Cao C., Lawrence D.A., Strickland D.K., Zhang L. A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood 2005, 106:3234-3241.
78. Gomez I.G., Tang J., Wilson C.L., Yan W., Heinecke J.W., Harlan J.M., et al. Metalloproteinase-mediated Shedding of Integrin beta2 promotes macrophage efflux from inflammatory sites. J. Biol. Chem. 2012, 287:4581-4589.
79. Gautier E.L., Ivanov S., Lesnik P., Randolph G.J. Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. Blood 2013, 122:2714-2722.
80. Llodra J., Angeli V., Liu J., Trogan E., Fisher E.A., Randolph G.J. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:11779-11784.
81. Gerrity R.G. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am. J. Pathol. 1981, 103:191-200.
82. Faggiotto A., Ross R., Harker L. Studies of hypercholesterolemia in the nonhuman primate, I. Changes that lead to fatty streak formation. Arteriosclerosis 1984, 4:323-340.
83. Feig J.E., Rong J.X., Shamir R., Sanson M., Vengrenyuk Y., Liu J., et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7166-7171.
84. van Gils J.M., Derby M.C., Fernandes L.R., Ramkhelawon B., Ray T.D., Rayner K.J., et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat. Immunol. 2012, 13:136-143.
85. Feig J.E., Vengrenyuk Y., Reiser V., Wu C., Statnikov A., Aliferis C.F., et al. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS ONE 2012, 7:e39790.
86. Gleissner C.A., Shaked I., Little K.M., Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J. Immunol. 2010, 184:4810-4818.
87. Kadl A., Meher A.K., Sharma P.R., Lee M.Y., Doran A.C., Johnstone S.R., et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 2010, 107:737-746.
88. Chinetti-Gbaguidi G., Colin S., Staels B. Macrophage subsets in atherosclerosis. Nat. Rev. Cardiol. 2015, 12:10-17.
89. Khallou-Laschet J., Varthaman A., Fornasa G., Compain C., Gaston A.T., Clement M., et al. Macrophage plasticity in experimental atherosclerosis. PLoS ONE 2010, 5:e8852.
90. Feig J.E., Parathath S., Rong J.X., Mick S.L., Vengrenyuk Y., Grauer L., et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011, 123:989-998.
91. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
92. Murray P.J., Wynn T.A. Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol. 2011, 89:557-563.
93. Hirata Y., Tabata M., Kurobe H., Motoki T., Akaike M., Nishio C., et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J. Am. Coll. Cardiol. 2011, 58:248-255.
94. Fadini G.P., Simoni F., Cappellari R., Vitturi N., Galasso S., Vigili de Kreutzenberg S., et al. Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. Atherosclerosis 2014, 237:805-808.
95. Chinetti-Gbaguidi G., Baron M., Bouhlel M.A., Vanhoutte J., Copin C., Sebti Y., et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ. Res. 2011, 108:985-995.
96. Stoger J.L., Gijbels M.J., van der Velden S., Manca M., van der Loos C.M., Biessen E.A., et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012, 225:461-468.
97. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011, 11:750-761.
98. Schrijvers D.M., De Meyer G.R., Kockx M.M., Herman A.G., Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1256-1261.
99. Silvestre-Roig C., de Winther M.P., Weber C., Daemen M.J., Lutgens E., Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ. Res. 2014, 114:214-226.
100. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
101. Poon I.K., Lucas C.D., Rossi A.G., Ravichandran K.S. Apoptotic cell clearance: basic biology and therapeutic potential. Nat. Rev. Immunol. 2014, 14:166-180.
102. Ravichandran K.S. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011, 35:445-455.
103. Lauber K., Bohn E., Krober S.M., Xiao Y.J., Blumenthal S.G., Lindemann R.K., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113:717-730.
104. Aprahamian T., Rifkin I., Bonegio R., Hugel B., Freyssinet J.M., Sato K., et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 2004, 199:1121-1131.
105. Goncalves I., Edsfeldt A., Ko N.Y., Grufman H., Berg K., Bjorkbacka H., et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1505-1512.
106. Nofer J.R., Bot M., Brodde M., Taylor P.J., Salm P., Brinkmann V., et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007, 115:501-508.
107. Poti F., Gualtieri F., Sacchi S., Weissen-Plenz G., Varga G., Brodde M., et al. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1505-1512.
108. Jaillon S., Jeannin P., Hamon Y., Fremaux I., Doni A., Bottazzi B., et al. Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ. 2009, 16:465-474.
109. Lewis M.J., Malik T.H., Ehrenstein M.R., Boyle J.J., Botto M., Haskard D.O. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009, 120:417-426.
110. Moura R., Tjwa M., Vandervoort P., Van Kerckhoven S., Holvoet P., Hoylaerts M.F. Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE-/- mice. Circ. Res. 2008, 103:1181-1189.
111. Ait-Oufella H., Kinugawa K., Zoll J., Simon T., Boddaert J., Heeneman S., et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 2007, 115:2168-2177.
112. Deroide N., Li X., Lerouet D., Van Vre E., Baker L., Harrison J., et al. MFGE8 inhibits inflammasome-induced IL-1beta production and limits postischemic cerebral injury. J. Clin. Investig. 2013, 123:1176-1181.
113. Ait-Oufella H., Pouresmail V., Simon T., Blanc-Brude O., Kinugawa K., Merval R., et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1429-1431.
114. Thorp E., Cui D., Schrijvers D.M., Kuriakose G., Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1421-1428.
115. Thorp E., Vaisar T., Subramanian M., Mautner L., Blobel C., Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cdelta, and p38 mitogen-activated protein kinase (MAPK). J. Biol. Chem. 2011, 286:33335-33344.
116. Sather S., Kenyon K.D., Lefkowitz J.B., Liang X., Varnum B.C., Henson P.M., et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007, 109:1026-1033.
117. Driscoll W.S., Vaisar T., Tang J., Wilson C.L., Raines E.W. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. Circ. Res. 2013, 113:52-61.
118. Boisvert W.A., Rose D.M., Boullier A., Quehenberger O., Sydlaske A., Johnson K.A., et al. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler. Thromb. Vasc. Biol. 2006, 26:563-569.
119. Kojima Y., Downing K., Kundu R., Miller C., Dewey F., Lancero H., et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J. Clin. Investig. 2014, 124:1083-1097.
120. Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334.
121. Heo K.S., Cushman H.J., Akaike M., Woo C.H., Wang X., Qiu X., et al. ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis. Circulation 2014, 130:180-191.
122. Marsch E., Theelen T.L., Demandt J.A., Jeurissen M., van Gink M., Verjans R., et al. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2545-2553.
123. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat. Rev. Drug Discov. 2011, 10:365-376.
124. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 2009, 8:23-33.
125. Koenen R.R., Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol. Med. 2011, 3:713-725.
126. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
127. Libby P., Tabas I., Fredman G., Fisher E.A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 2014, 114:1867-1879.
128. Gobbetti T., Coldewey S.M., Chen J., McArthur S., le Faouder P., Cenac N., et al. Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:18685-18690.
129. Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.
130. Mulder W.J., Jaffer F.A., Fayad Z.A., Nahrendorf M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci. Transl. Med. 2014, 6:239sr1.
131. Schiener M., Hossann M., Viola J.R., Ortega-Gomez A., Weber C., Lauber K., et al. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol. Med. 2014, 20:271-281.
132. Fredman G., Kamaly N., Spolitu S., Ghorpade D., Kuriakose G., Milton J., Perretti M., Farokhad O., Tabas I. Targeted nanoparticles containing the pro-resolving peptide Ac2-26 protect against advanced atherosclerosis. Sci. Transl. Med. 2015, 7:275ra20.
133. Kamaly N., Fredman G., Subramanian M., Gadde S., Pesic A., Cheung L., et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:6506-6511.
134. Arur S., Uche U.E., Rezaul K., Fong M., Scranton V., Cowan A.E., et al. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev. Cell 2003, 4:587-598.
135. Li Y., Cai L., Wang H., Wu P., Gu W., Chen Y., et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 2011, 30:3887-3899.
136. Cash J.L., Hart R., Russ A., Dixon J.P., Colledge W.H., Doran J., et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 2008, 205:767-775.
137. Cash J.L., Bena S., Headland S.E., McArthur S., Brancaleone V., Perretti M. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23. EMBO Rep. 2013, 14:999-1007.
138. Cash J.L., Christian A.R., Greaves D.R. Chemerin peptides promote phagocytosis in a ChemR23- and Syk-dependent manner. J. Immunol. 2010, 184:5315-5324.
139. Serhan C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014, 510:92-101.
140. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J.N., Petasis N.A., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7671-7676.
141. Haworth O., Cernadas M., Yang R., Serhan C.N., Levy B.D. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 2008, 9:873-879.
142. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8247-8252.
143. Norling L.V., Spite M., Yang R., Flower R.J., Perretti M., Serhan C.N. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J. Immunol. 2011, 186:5543-5547.
144. Li S., Sun Y., Liang C.P., Thorp E.B., Han S., Jehle A.W., et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ. Res. 2009, 105:1072-1082.
145. Brown J.M., Chung S., Sawyer J.K., Degirolamo C., Alger H.M., Nguyen T.M., et al. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:24-30.
146. Degirolamo C., Kelley K.L., Wilson M.D., Rudel L.L. Dietary n-3 LCPUFA from fish oil but not alpha-linolenic acid-derived LCPUFA confers atheroprotection in mice. J. Lipid Res. 2010, 51:1897-1905.
147. Nakajima K., Yamashita T., Kita T., Takeda M., Sasaki N., Kasahara K., et al. Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1963-1972.
148. Wan J.B., Huang L.L., Rong R., Tan R., Wang J., Kang J.X. Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2487-2494.
149. Halvorsen S., Andreotti F., ten Berg J.M., Cattaneo M., Coccheri S., Marchioli R., et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J. Am. Coll. Cardiol. 2014, 64:319-327.
150. Rayner K.J., Sheedy F.J., Esau C.C., Hussain F.N., Temel R.E., Parathath S., et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Investig. 2011, 121:2921-2931.
151. Shaw J.A., Bobik A., Murphy A., Kanellakis P., Blombery P., Mukhamedova N., et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 2008, 103:1084-1091.
152. Cardilo-Reis L., Gruber S., Schreier S.M., Drechsler M., Papac-Milicevic N., Weber C., et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol. Med. 2012, 4:1072-1086.
153. Courties G., Heidt T., Sebas M., Iwamoto Y., Jeon D., Truelove J., et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 2014, 63:1556-1566.
154. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
155. Vucic E., Calcagno C., Dickson S.D., Rudd J.H., Hayashi K., Bucerius J., et al. Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC Cardiovasc. Imaging 2012, 5:819-828.